bioihbjkbjnl/mcl2 huggingface dataset:
Expression of microRNA-133a and microRNA-208b in Acute Myocardial Infarction
Condition: Myocardial Infarction, Acute
MeSH terms: Myocardial Infarction; Infarction
Study type: Observational [Patient Registry]

Summary: 
      Cardiac-enriched micro-RNAs (miRNAs), micro RNA 208b and 133a(MiR-208b, MiR-133a))
      corresponds to the health and disorders of the cardiovascular system. An intron of the
      cardiac myosin heavy chain gene MYH7 encodes miR-208b. It is found on chromosome 14 in
      humans. Identify new diagnostic biomarkers based on miRNAs, researchers examine the
      expression of miR-133a and 208b at various time points (04 hours, 08 hours, 12 hours, 24
      hours, 48 hours) following the development of the infarct and compared it to the traditional
      myocardial infarction biomarkers cardiac troponine (cTnl) and Creatine kinase-MB (CK-MB).
    

Detailed description: 
      The 98% of human genes are non-coding RNA, which is further divided into long non-coding RNA
      (lncRNA, > 200 bp) and short non-coding RNA (200 bp, including microRNA (miRNA) and circular
      RNA). More than 2000 human miRNAs have been discovered, and it seems that they regulate
      around 60% of human genes.Through a number of pathways, miRNAs control the development,
      re-modelling, and regeneration of the heart as well as endothelial function, vasculo-genesis,
      and neoangiogenesis. 30% of the genes in the human genome are regulated by about 1000 miRNAs.
      Endogenous miRNAs are 19-22 nucleotide single-stranded RNA molecules that frequently target
      the 3' untranslated regions (3'-UTR) of mRNAs to regulate gene expression at the
      post-transcriptional level in physiological processes, disease development, and conditions
      like cancer, autoimmune and inflammatory diseases, neuro-degenerative diseases, and
      cardiovascular diseases. Cardiac-enriched miRNAs, MiR-208 in health and disorders of the
      cardiovascular system are investigated.

      Identify new diagnostic biomarkers based on miRNAs, researchers examine the expression of
      miR-133a and 208b at various time points (04 hours, 08 hours, 12 hours, 24 hours, 48 hours)
      following the development of the infarct and compared it to the traditional myocardial
      infarction biomarkers cTnl and CK-MB.
    

Intervention name(s): No intervention
Intervention type(s): Other
Intervention description(s): Expression of miR-133a &208b at 4, 8, 12, 24 and 48 hours from the first appearance of myocardial infarction (MI) symptoms
Other intervention name(s): Expression of miR-133a & 208b
Observational model: Case-Only
Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        Patient registering at the Coronary Care Unit at Ain-shams University hospital German
        University in Cairo, New Cairo City,.Egypt
PPIO-006 Primary Tumor Resection for IVa NSCLC
Condition: Non-small-cell Lung Cancer (NSCLC)
MeSH terms: Lung Neoplasms; Carcinoma, Non-Small-Cell Lung
Study type: Observational

Summary: 
      The goal of this mutli-center observational study is toinvestigate the impact of primary
      tumor resection (PTR) on the long-term survival of patients with non-small-cell lung cancer
      (NSCLC) and dry pleural dissemination (DPD). The main question it aims to answer is: whether
      primary tumor resection improve long-term survival of NSCLC patients with dry pleural
      dissemination.
    

Detailed description: 
      Non-small-cell lung cancer (NSCLC) patients with dry pleural dissemination have poor survival
      rates and are generally contraindicated for surgery. Previous single-center retrospective
      studies have suggested that these patients may benefit from primary tumor resection (PTR).
      However, the evidence supporting PTR is still limited, especially in the era of targeted
      therapy. This study aimed to investigate the impact of PTR on the long-term survival of
      patients with NSCLC and DPD.
    

Intervention name(s): Primary tumor resection or not
Intervention type(s): Procedure
Intervention description(s): For patients with non-small-cell lung cancer (NSCLC) and dry pleural dissemination, surgical decisions to perform exploratory thoracotomy only or primary tumor resection with wedge resection, segmentectomy, or lobectomy were based on surgeon experience and patient preference.
Observational model: Cohort
Time perspective: Retrospective
Sampling method: Non-Probability Sample
Study population: 
        From January 2016 to December 2023, a total of 204 consecutive NSCLC patients with
        surgically confirmed DPD were collected retrospectively from three high-volume centers in
        China. Data were obtained by reviewing medical records.
Effects of Creatine Supplementation in Addition to Resistance Exercise Training in Patients With Knee Osteoarthritis
Condition: Knee Osteoarthritis
MeSH terms: Osteoarthritis; Osteoarthritis, Knee
Study type: Interventional

Summary: 
      Despite the past decade being dedicated to bone and joint disease, the incidence and
      prevalence rates of osteoarthritis continues to rise, and till date not curative treatment
      has been identified for the management of knee osteoarthritis. In terms of conservative
      management of knee osteoarthritis, pharmacological management has been the mainstay of
      treatment, however is associated with numerous adverse effects with prolonged use, and it is
      important to look into the non-pharmacological alternates for the management of knee
      osteoarthritis. Research has shown resistance exercise training to be the most effective
      non-pharmacological treatment option for the management of knee osteoarthritis, and the
      purpose of the current study is to determine if the addition of a non-pharmacological dietry
      supplement like creatine can amplify the beneficial effects of resistance exercise training
      in patients with knee osteoarthritis.
    


Intervention name(s): Lower Extremity Resistance Exercise Training; Home Exercise Plan; Electrotherapy + Heating; Joint Mobilization; Creatine Supplementation
Intervention type(s): Other; Other; Device; Procedure; Dietary Supplement
Intervention description(s): Treadmill walking 5-10 min for warm up Strength training: (80% of 8RM)
3 times supervised exercise for 4 weeks Warm up (Self Paced walking for 10 minutes) leg press, leg extension, Sit to stand squat (mini squats) Stationary Cycling (Maximum Resistance as per patient tolerance till failure)
3 sets 8 reps 10-15 s rep rest interval 1-2 min set rest interval; 2 sets of 10 repetitions/day of
AROM isolated knee extension and knee flexion Isometric isolated knee extension and knee flexion Isometric terminal knee extension Sit to stand squat Isometric knee terminal extension; Interferential Current therapy (2P), in combination with heating pad for 20 minutes; Tibio-femoral Anterior Glide Tibio-femoral Posterior Glide Patellofemoral Joint Mobilization; Creatine Supplementation 20g/day for 1 week followed by 5 g/day for 3 weeks
Other intervention name(s): Lower Extremity Strength Training; Manual Therapy
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary purpose: Treatment
Effect of Repeated Administration of Liraglutide on Insulinogenic Indices
Condition: Healthy
Study type: Interventional
Phase: Phase 4

Summary: 
      The study investigates the effect of glucagon-like peptide receptor 1 agonist, liraglutide,
      on insulin secretion. Study hypothesis: the effect of liraglutide on insulin release may
      change after repeated administration. The effect of liraglutide on insulin release will be
      tested using graded glucose infusion test (GGIT) in healthy volunteers. GGIT will be
      performed without medication and repeated 12 hours after first dose of liraglutide and after
      3 weeks of treatment with liraglutide.
    


Intervention name(s): Liraglutide
Intervention type(s): Drug
Intervention description(s): Graded glucose infusion test (GGIT)will be performed on baseline. 1 week later treatment with liraglutide 0.6mg/day (injected between 21.00-23.00) will be initiated.
GGIT will be repeated 12 hours after first injection and after 21 days on-treatment (12 hours after last injection).
Other intervention name(s): Victoza
Intervention MeSH terms: Liraglutide
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Evaluation Study of the Online High School Media Aware Program
Condition: Sexual Behavior
Study type: Interventional

Summary: 
      The main aim of this study is to conduct a pretest-posttest RCT with a three-month follow-up
      to investigate the sustainability of outcomes in students who use the Media Aware program.
      Media Aware, a web-based media literacy education program for high school students to promote
      sexual and relationship health. Media Aware is designed to provide high school students with
      sexual health knowledge, media literacy skills, and the skills to make healthy decisions
      about sexual activity. This study will examine if behavioral indicators among students in the
      intervention group sustain, emerge, or diminish over time compared to students in the delayed
      intervention group.
    


Intervention name(s): Media Aware Sexual Health - High School
Intervention type(s): Other
Intervention description(s): Media Aware is an online media literacy and sexual health education program developed for high school students that addresses the influence of media on sexual behaviors explicitly using established message processing theory. The program consists of 4 self-paced modules each with two to three lessons. Broadly, the modules cover healthy and unhealthy relationships, sexually transmitted infections, consent, substance use, pregnancy, protection and contraception, and communication between adolescents and their partners, parents, or health providers. Users also learn media literacy skills including message deconstruction to help examine the truth behind media messages.
Other intervention name(s): Media Aware
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Prevention
Keywords: Adolescent sexual health; Media literacy education; Web-based programming
Nissen and Gastroplasty in Gastroesophageal Reflux Disease (GERD)
Condition: Gastroesophageal Reflux Disease; Hiatal Hernia; Barrett's Esophagus; Esophagitis; Dysphagia
MeSH terms: Barrett Esophagus; Gastroesophageal Reflux; Esophagitis, Peptic; Esophagitis; Hernia, Hiatal
Study type: Interventional
Phase: Phase 4

Summary: 
      Laparoscopic Nissen Fundoplication has established itself as the procedure of choice in the
      surgical management of the majority of patients suffering from gastroesophageal reflux
      disease (GERD). Postoperative paraesophageal herniation has incidence ranges up to 7% in the
      immediate postoperative period. This randomized controlled study was scheduled to investigate
      the role of the posterior gastropexy, in combination with laparoscopic Nissen fundoplication,
      in prevention of paraesophageal herniation and improvement of postoperative results, in
      surgical treatment of GERD.
    


Intervention name(s): Nissen; Gastropexy
Intervention type(s): Procedure; Procedure
Intervention description(s): Laparoscopic Nissen Fundoplication; posterior gastropexy
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary purpose: Treatment
A Study of the Efficacy and Safety of Topiramate in the Treatment fo Obese, Type 2 Diabetic Patients Treated With Metformin
Condition: Obesity; Diabetes Mellitus, Type 2; Diabetes Mellitus, Adult-Onset
MeSH terms: Diabetes Mellitus; Diabetes Mellitus, Type 2
Study type: Interventional
Phase: Phase 3

Summary: 
      The purpose of this study is to compare the efficacy (in terms of weight and hemoglobin type
      A1c [HbA1c]) and safety of topiramate (96 milligrams[mg] or 192 mg daily) with placebo in the
      treatment of obesity in Type 2 diabetic patients receiving metformin.
    

Detailed description: 
      Topiramate is not approved for the treatment of obesity. This double-blind,
      placebo-controlled study is designed to assess the efficacy and safety of topiramate in Type
      2 diabetic patients with obesity who are well-controlled on metformin alone. Patients are
      randomized to receive either topiramate (up to a target dose of 96 or 192 mg per day) or
      placebo for one year. Assessments of efficacy include weight reduction, levels of HbA1c
      (shows average blood sugar level over a few months), Body Mass Index (BMI), and Health
      Related Quality of Life (HRQOL) measures. Safety evaluations (incidence of adverse events,
      vital signs, hypoglycemic events, electrocardiograms [ECGs], clinical laboratory values) are
      monitored throughout the study. The study hypothesis is that topiramate, combined with
      metformin and non-pharmacologic therapy, can effectively achieve significant weight reduction
      and is well tolerated. During the first 8 weeks, oral doses of matching placebo or topiramate
      are increased gradually to target dose (96 milligrams[mg] or 192mg daily); the dose will be
      maintained for 1 year, then gradually reduced and stopped
    

Intervention name(s): topiramate
Intervention type(s): Drug
Intervention MeSH terms: Topiramate
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double
Primary purpose: Treatment
Keywords: Type 2 Diabetes; Obesity; Metformin; Hemoglobin A1c; Adult-Onset Diabetes Mellitus (AODM)
A Safety, Tolerability, PD and PK Study in Healthy Adults
Condition: Healthy
Study type: Interventional
Phase: Phase 1

Summary: 
      The primary objective of this study is to evaluate the safety, tolerability, pharmacodynamics
      (PD) and pharmacokinetics (PK) of TRV734 given as a single dose (Part A) and as multiple
      ascending doses (Part B) in healthy subjects.
    

Detailed description: 
      This will be conducted in two-parts enrolling a total of approximately 72 healthy volunteers.

        -  Part A will assess the safety, tolerability, PD and PK of a 125mg dose of TRV734 in an
           open-label, randomized, three-period crossover study in which subjects are fasted, fed a
           standard meal, or fed a high-fat meal.

        -  Part B of the trial will assess the safety, tolerability, PD and PK of multiple
           ascending doses of TRV734 in a double blind, double dummy, randomized, active- and
           placebo-controlled, adaptive study. Oxycodone immediate release (IR) 10 mg will be used
           as a benchmark.
    

Intervention name(s): Open-label TRV734 125 mg; TRV734 blinded; Oxycodone IR 10 mg; Placebo
Intervention type(s): Drug; Drug; Drug; Drug
Intervention description(s): 125 mg; blinded, multiple ascending dose; TRV734-matched and oxycodone placebo
Intervention MeSH terms: Oxycodone
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Keywords: Healthy; Pharmacodynamics (PD); Pharmacokinetics (PK)
Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial
Condition: Pancreatic Ductal Adenocarcinoma
MeSH terms: Adenocarcinoma
Study type: Interventional
Phase: Phase 2

Summary: 
      Pancreatic ductal adenocarcinoma is the fourth cause of death in the Western world. Surgery
      remains the only treatment offering an advantage in terms of overall survival (5-year
      survival range, 15-25%), but unfortunately only 10-20% of patients present resectable disease
      at the time of diagnosis. Since the approval of gemcitabine as a standard treatment for
      advanced pancreatic patients, no drug or combination of drugs has significantly improved the
      prognosis. Recently, as compared with gemcitabine, FOLFIRINOX was associated with a survival
      advantage (11.1 vs 6.8 months), but had increased toxicity. In some retrospective studies,
      modified FOLFIRINOX regimen (60/120 mg/m2 of oxaliplatin and irinotecan) has an improved
      safety profile in digestive malignancies. The purpose of this phase II multicenter study was
      to investigate the efficacy and safety in patients with pancreatic cancer who progressed in
      gemcitabine-based first line chemotherapy.
    


Intervention name(s): modified FOLFIRINOX regimen
Intervention type(s): Drug
Intervention description(s): Modified FOLFIRINOX regimen consisted of oxaliplatin at a dose of 60 mg per square meter, given as a 2-hour intravenous infusion, after 60 minutes, of irinotecan at a dose of 120 mg per square meter, given as a 90-minute intravenous infusion, immediately followed by leucovorin at a dose of 400 mg per square meter, given as a 2-hour intravenous infusion through a Y-connector. This treatment was immediately followed by fluorouracil at a dose of 400 mg per square meter, administered by intravenous bolus, followed by a continuous intravenous infusion of 2400 mg per square meter over a 46-hour period every 2 weeks
Intervention MeSH terms: Folfirinox
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Study of Vinorelbine and Cisplatin as Induction Therapy With Radiotherapy in Patients With Unresectable NSCLC
Condition: Lung Cancer
MeSH terms: Lung Neoplasms
Study type: Interventional
Phase: Phase 2

Summary: 
      Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as
      induction therapy and subsequent concomitantly with radiotherapy (RT) in patients with lung
      cancer (NSCLC) locally advanced unresectable
    

Detailed description: 
      Hypothesis: At present, administration of concomitant chemotherapy and radiation therapy is
      considered a treatment of choice for patients with unresectable stage III tumor selected
      clinically.

      There is at present a systemic considered standard treatment in combination with radical
      radiotherapy. Nor is it established a dose of standard radiation therapy, but it is known
      that should never be less than 60Gy57.

      Vinorelbine has shown a strong radio-sensitizer in-vitro37 effect. In the phase II study, The
      combination of oral vinorelbine with cisplatin as induction therapy and then concomitantly
      with radiotherapy (66Gy) has provided very encouraging efficacy results. Recently in the
      vortex scheme cisplatin study with oral vinorelbine concomitant maintained with radiation
      from the second cycle of chemotherapy was tested.

      It is therefore a priority in this segment pathology seeking treatment regimens that improve
      the effectiveness and toxicity. Metronomic chemotherapy started with the idea of
      administering a cytostatic divided doses, for an extended period without interruption, can
      provide the advantage of exposing patients to significant dose chemotherapy without worsening
      the toxicity profile. All this makes it an attractive treatment strategy, and can also
      maintain radio sensitizing effect during concomitance.
    

Intervention name(s): Vinorelbine; Cisplatin; Vinorelbine; Cisplatin; Radiotherapy
Intervention type(s): Drug; Drug; Drug; Drug; Radiation
Intervention description(s): Cycle 1 and 2 50 mg/day, (Monday, Wednesday and Friday); Cycle 1 and 2 day 1, 80 mg/m2; Cycle 3 and 4 30 mg/day, (Monday, Wednesday and Friday); Cycle 3 and 4 day 1, 80 mg/m2; concomitant therapy during cycles 3 and 4. Total dose: 66Gy
Other intervention name(s): Navelbine; Navelbine
Intervention MeSH terms: Cisplatin; Vinorelbine
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Lung Cancer; Cancer Lung Disease; NORA; GECP 15/02; Metronomic administration
Nebulized Hypertonic Saline Treatment in Hospitalized Children With Moderate to Severe Viral Bronchiolitis
Condition: Bronchiolitis
MeSH terms: Bronchiolitis; Bronchiolitis, Viral
Study type: Interventional

Summary: 
      The purpose of this study is planned to investigate whether frequently inhaled hypertonic
      saline (HS) can relieve symptoms and signs faster than normal saline (NS) and shorten length
      of stay (LOS) significantly for moderately to severely ill infants with bronchiolitis without
      apparent adverse effects.
    

Detailed description: 
      The treatment of bronchiolitis remains largely supportive with mechanical ventilatory support
      as needed .Other types of treatment remain controversial.We and other researchers have
      demonstrated that nebulized HS and bronchodilators decreased symptoms and LOS for infants
      with mild to moderate viral bronchiolitis .All the aforementioned studies used 3 times per
      day dosing, which is significantly less than the 3 to 6 times per hour regimens often used in
      children in respiratory distress.Frequently nebulized HS reduced the LOS for infants with
      moderately severe bronchiolitis.The present study is planned to investigate whether
      frequently inhaled HS can relieve symptoms and signs faster than NS and shorten LOS
      significantly for moderately to severely ill infants with bronchiolitis without apparent
      adverse effects.

      PMID: 15266547 PMID: 12576370 PMID: 16599051 PMID: 17719935 PMID: 20014350 PMID: 12475841
    

Intervention name(s): 3% hypertonic saline; normal saline
Intervention type(s): Drug; Drug
Intervention description(s): Moderately to severely ill infants with bronchiolitis were randomized to receive 4 mL solution containing either 3% hypertonic saline or normal saline; Moderately to severely ill infants with bronchiolitis were randomized to receive 4 mL solution containing either 3% hypertonic saline or normal saline
Other intervention name(s): normal saline; 3% hypertonic saline
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: Hypertonic saline solution, bronchiolitis, RSV